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Abstract
Background: The expanding research in the field of long non-coding RNAs
(lncRNAs) showed abnormal expression of lncRNAs in many complex diseases.
Accurately identifying lncRNA-disease association is essential in understanding
lncRNA functionality and disease mechanism. There are many machine learn-
ing techniques involved in the prediction of lncRNA-disease association which
use different biological interaction networks and associated features. Feature
learning from the network structured data is one of the limiting factors of ma-
chine learning-based methods. Graph neural network based techniques solve
this limitation by unsupervised feature learning. Deep belief networks (DBN)
are recently used in biological network analysis to learn the latent representa-
tions of network features.
Method: In this paper, we propose a DBN based lncRNA-disease associ-
ation prediction model (DBNLDA) from lncRNA, disease and miRNA inter-
actions. The architecture contains three major modules- network construc-
tion, DBN based feature learning and neural network-based prediction. First,
we constructed three heterogeneous networks such as lncRNA-miRNA similar-
ity (LMS), disease-miRNA similarity (DMS) and lncRNA-disease association
(LDA) network. From the node embedding matrices of similarity networks,
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lncRNA-disease representations were learned separately by two DBN based sub-
networks. The joint representation of lncRNA-disease was learned by a third
DBN from outputs of the two subnetworks mentioned. This joint feature rep-
resentation was used to predict the association score by an ANN classifier.
Results: The proposed method obtained AUC of 0.96 and AUPR of 0.967 when
tested against standard dataset used by the state-of-the-art methods. Analy-
sis on breast, lung and stomach cancer cases also affirmed the effectiveness of
DBNLDA in predicting significant lncRNA-disease associations.
Availability: https://github.com/manumad/DBNLDA
Keywords: long non-coding RNA, Deep Belief Network, lncRNA-disease
association, Deep Learning, Functional similarity networks, unspervised
feaeture learning
1. Introduction
Long non-coding RNAs (lncRNA) are RNA transcripts with more than 200
nucleotides in length and lack of protein-coding potential [1]. The studies re-
vealed that lncRNAs were involved as a regulator in many biological processes
such as ageing, cell differentiation, epigenetic mechanisms and protein synthesis
[2]. The aberrant expression of lncRNAs is also associated with many complex
diseases like cancers [3], alzheimer’s disease [4], and heart failure [5]. Therefore,
identifying the role of lncRNAs in diseases will help to improve the understand-
ing of the disease mechanisms and derive new insights on drug therapeutics
[6].
An array of computational models to predict the lncRNA-disease association
are available in the literature with varying performance. All these works utilise
varieties of lncRNA features from known lncRNA-disease associations and their
interactions with other molecules like micorRNAs (miRNA), proteins and mes-
sengerRNAs (mRNA). There are three major categories of works in lncRNA-
disease association. The first category of works utilise the knowledge of lncRNA
functional similarity under the assumption that functionally similar lncRNAs
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associate with similar diseases. Based on this assumption, an lncRNA-disease
association network was constructed. Then, algorithms from machine learning
and social network analysis were used to make the lncRNA-disease prediction.
For example, methods such as RWRlncD [7], IRWRLDA [8], BRWLDA [9] used
various random walk algorithm and KATZLDA [10] applied Katz page ranking
algorithm for analysing the similarity network. All these methods relied upon
the network structure features and results were biased towards nodes having
high degree and centrality.
The advanced research on lncRNA mechanism revealed that the regulation
of lncRNA is largely determined by co-expressed miRNAs [11]. The second cat-
egory of works used expression levels of lncRNAs, genes and miRNAs in various
diseases. The earlier methods [12] in this category used experimentally vali-
dated disease associated genes/miRNAs and lncRNA co-expression data. These
methods were not useful with lncRNAs which have no experimentally validated
gene/miRNA interaction. Recent works under this category used mathematical
models such as matrix completion [13], matrix factorization [14] and Graph-
based algorithms (TPGLDA [15], DisLncPri [16]) to predict lncRNA-disease
association.
The third category of works constructed a heterogeneous interaction network
based on lncRNA, miRNA and mRNA functional similarity and associations.
Machine learning techniques such as Random Walk [12], Support Vector Ma-
chine (SVM) [17], and Laplacian regularised least square method [18] have found
use in the analysis of these networks. Major challenge in the above methods
was the effective representation of lncRNA-disease features. Introduction of
deep learning models eliminated the need for feature extraction by enabling
unsupervised representation learning. Among them, CNNLDA [19] used con-
volutional neural networks and GCNLDA [20] used graph convolutional neural
networks [21] to learn global representations of lncRNA, miRNA and disease
nodes. A recent work titled GAMCLDA [22] used graph autoencoder and ma-
trix completion to predict lncRNA-disease association.
Deep learning algorithms such as Deep Belief Networks (DBN) were used
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recently in computer vision and text mining to learn the latent representation of
the data [23]. A DBN model has stacked layers of Restricted Boltzman Machines
(RBM), which contains visible layers and hidden layers to compute probability
distribution as latent representation. DBN based models were successfully used
in Bioinformatics to predict drug-target [24], multiple types of miRNA-disease
association [25, 26] and cancer sub-type prediction [27], but not applied in the
field of lncRNA-disease association prediction.
In this study, we propose a DBN based representation learning model (called
DBNLDA) for lncRNA-disease association prediction. DBNLDA make use of
heterogeneous information on functional similarity, co-expression and interac-
tions between lncRNAs and diseases for making the prediction. The architec-
ture of DBNLDA contains 3 modules namely-(i)network construction, (ii) DBN
based feature learning and (iii) association prediction. Summary of the proposed
architecture is depicted in Figure 1. Instead of using a single heterogeneous net-
work of lncRNAs, miRNAs and diseases as in previous works [12, 20], DBNLDA
constructs three functional similarity networks such as lncRNA-miRNA (LMS),
disease-miRNA (DMS) and lncRNA-Disease association (LDA). Then, for each
pair of lncRNA-disease, DBN subnetwork-1 learns lncRNA and disease repre-
sentations from their functional associations with miRNAs. Similarly, DBN
subnetwork-2 learns lncRNA-disease representations from LDA network. The
representations learned by subnetworks are combined for learning higher-level
representation using the third DBN (DBN-combined). In order to reduce the
obstructive impact of features learned from sparse network, the features from
DBN-combined are recomputed using an attention layer. In the final stage, a
neural network-based classifier is used to predict the lncRNA-disease associa-
tion based on the joint feature representation. A 5-fold cross-validation and
case studies on cancer dataset showed that DBNLDA significantly improves the
performance and potential lncRNA-disease association prediction.
The remainder of the paper is organized as follows. Section 2 gives a de-
tailed discussion of DBNLDA architecture. Section 3 discusses the results of
the proposed method and Section 4 concludes the paper.
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Figure 1: Architecture of DBNLDA. LMS:LncRNA-miRNA similarity; DMS: Disease-miRNA
similarity; LDA: LncRNA-Disease Association; L:embedding of lncRNAs from LMS; D: em-
bedding of diseases from DMS; LD: embedding of lncRNAs and diseases from LDA; DBN:
Deep Belief Network.
2. Materials and Methods
2.1. The Dataset
Datasets used in the previous reports [12, 20, 14] were used for lncRNA-
Disease associations, lncRNA-miRNA interaction, lncRNA function similar-
ity and disease semantic similarity. LncRNA-disease associations were down-
loaded from two reference databases: LncRNADisease [28] and lnc2cancer [29].
MiRNA-lncRNA interactions and miRNA-disease interactions were downloaded
from miRNet [30] and Starbase [31] databases respectively. All these down-
loaded associations and similarities were then compiled for 240 lncRNAs, 412
diseases, 495 miRNAs and 2697 known lncRNA- disease interactions. These
known interaction pairs constituted the positive example for training the model.
All other pairs between lncRNAs and diseases, which were not listed in reference
databases, were considered to be negative interactions. We randomly selected
2967 samples from negative interactions to construct a balanced dataset. Sum-
mary of the dataset is given in Table 1.
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Table 1: Summary of dataset
Particular Count
LncRNAs 290
Diseases 412
MiRNAs 495
Positive pairs 2697
Negative pairs 2697
2.2. Construction of LMS, DMS and LDA networks
The first step in the DBNLDA architecture was the construction of three sim-
ilarity networks such as LMS, DMS and LDA as defined in Section 1. Let nl, nm,
and nd be the number of lncRNAs, miRNAs and diseases in the dataset. LMS
network (with nl lncRNAs and nm miRNAs) was constructed using lncRNA-
lncRNA similarity and lncRNA-miRNA interactions. LncRNA functional sim-
ilarities computed by Chen’s method [32] was adapted here, and an edge was
added if the similarity score was greater than 0. For the list of lncRNAs, the
known miRNA targets downloaded from the miRNet were used as lncRNA-
miRNA edges.
Similar to LMS, DMS network was constructed (with nd diseases and nm
miRNAs) using disease-disease similarities and known disease-miRNA associa-
tions. LncRNA-Disease association (LDA) network contains nl lncRNAs and nd
diseases, where an un-directed edge was used to represent the known association
between lncRNA and disease.
2.3. Computing node embedding features from networks
Node2vec [33] algorithm was used to get node embedding from each network.
Node2vec output a node representation based on the neighbourhood information
of the node. First, LMS network was passed through node2vec embedding layer,
and embedding matrix for lncRNA was obtained as Llms ∈ Rnl×e, where e
is the embedding dimension. The embedding matrix for diseases from DMS
was obtained as Ddms ∈ Rnd×e. Then, for each lncRNA-disease pair (l, d) in
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the dataset (both positive and negative examples), Llms[l] and Ddms[d] were
concatenated to form vector LDlmd[ld] ∈ R2e. This resulted in a feature matrix
LDlmd ∈ Rn×2e, where n is the total number of examples in the dataset. Finally,
the embedding matrices of lncRNAs and diseases, represented as Llda ∈ Rnl×e,
Dlda ∈ Rnd×e were obtained from LDA network. Then as in the case of LDlmd,
for each pairs of lncRNA-disease, vectors from Llda and Dlda were concatenated
to form feature matrix LDlda ∈ Rn×2e.
2.4. DBN based feature learning
Following the Node2vec embedding layer, DBNLDA implements Deep Belief
Network based feature learning. In this work, DBN was used to learn latent rep-
resentation of lncRNA and disease nodes and encode them to a new dimension
h, where h ≥ e. The architecture consisted of two DBN subnetworks- one to
learn lncRNA-disease representation from functional similarity networks (LMS
and DMS) and other from LDA network. The DBN subnetwork-1 received em-
bedded feature matrix LDlmd as input, and produce LDdb1 ∈ Rn×h (h, the
number of hidden units in DBN) as output. Similarly, the DBN subnetwork-2
received LDlda as input and produce LDdb2 ∈ Rn×h as output. Then both
LDdb1 and LDdb2 were concatenated to form combined feature representation,
LD ∈ Rn×2h. The network DBN-combined accepted LD as input and learn the
feature representation as LDdb ∈ Rn × h′, where h′ is the number of hidden
units in the DBN-combined and h′ ≥ h.
2.5. Feature attention layer
Since all the three networks used in the DBNLDA architecture were sparse
in nature, there was a chance of losing feature importance in the latent repre-
sentation learned by DBN. The attention mechanism in deep learning was used
to solve this issue by recomputing the feature values from all available infor-
mation so that their contributions could be different and unique. In this work,
attention mechanism similar to the one used in GCNLDA [20] was applied to
LDdb features.
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Let LDdbi = [ld
1
i , ld
2
i , ..., ld
h′
i ] represents the feature vector of i
th entry in the
dataset learned by DBN-combined, where ldki ∈ R,∀k = 1, 2, ...h′. The attention
score for each element in LDdbi was calculated by introducing attention weight
parameters Hatt ∈ Rh′×h′ , W att ∈ Rh′×h′ and bias batt ∈ Rh′ as in Equation 1.
αatti = Softmax(H
att · tanh(W attLDi + batt)) (1)
Next, the attention enhanced feature values were recomputed as in Equation
2.
LDatti = α
att
i ⊗ LDdbi (2)
where ⊗ represents pairwise multiplication. Finally, the matrix LDatt =
[LDatti ] was used as input for association prediction.
2.6. Prediction Layer
The final module of DBNLDA architecture is a neural network classifier to
predict the association between lncRNA and disease. The classifier network
followed a 1-2-1 structure, where the input layer has h′ nodes to receive input
from LDatt and output layer has one node to predict the association score. The
number of nodes in hidden layers kept as hyperparameter. Activation function
used in all layers except the output was Relu. In order to reduce the overfitting,
a dropout of 0.02 probability was added between the hidden layers. Output
layer used a sigmoid function to compute the association score. The network
used ADAM optimizer with learning rate 0.01 and binary cross-entropy loss
function.
2.7. Hyperparameters
Various hyperparameters determine the performance of DBNLDA in differ-
ent modules. The values of these hyperparameters were set empirically following
performance evaluation. The dimension of node2vec embedding, e is set to be
64 for all networks with keeping other parameters to default values in [33]. Fol-
lowing the implementation of [26], the DBN subnetworks in this work uses three
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Figure 2: Comparison of accuracy of DBNLDA model on different number of nodes in DBN
subnetworks (h) and DBN combined (h′). Points are annotated with (h, h′) values
stacked layers of RBM, with h = 128 nodes in all layers. The combined DBN
has dimension h′ = 256. It is found that very low values h and h′ degrade
the performance and high values have no effect on the performance (see Figure
2 for details). For the classification module, the number of neurons in both
hidden layers set as 128. The classifier iterate over 30 epochs, since the model
performance became stable after 30th epoch.
A detailed description DBNLDA steps and implementation details are avail-
able in SupplementaryFile-S1.pdf.
3. Results and Discussion
3.1. Performance evaluation metrics
We used 5-fold cross-validation to measure and compare the performance of
the model. The dataset consist of 5394 lncRNA-disease pairs (2697 positive asso-
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Figure 3: Learning Curve for different folds of 5-fold cross-validation
ciations and 2697 negative associations). The area under the receiver operating
characteristic (AUC-ROC) curve was used to compare the global performance
of the prediction model. The area under the precision-recall curve (AUPR) and
average accuracy were also used to measure the prediction performance.
3.2. Overall performance
The DBNLDA was trained over 30 epochs and the learning curve (refer
Figure 3) showed consistent characteristics in all folds of cross validation. The
model gave average AUC of 0.96 over cross validations and ROC curve is shown
in Figure 4. The model reported an accuracy of 0.957 and AUPR value of 0.968.
In order to analyse how DBN based features improve the performance of
the prediction model, we have repeated the experiments with different levels of
feature combinations. It is clear from the Table 2 that introduction of DBN
based learning significantly improved the accuracy of the prediction model.
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Figure 4: ROC curve for different folds of 5-fold cross-validation
3.3. Comparison with other methods
We compared the performance of DBNLDA with other state-of-the-art meth-
ods such as RFLDA [12], GCNLDA [20], SIMCLDA[13], Ping’s Method [34],
MFLDA [14], LDAP [17], GAMCLDA [22] and CNNLDA [19], based on area
under ROC curve (AUC) and Area under Precision-Recall curve (AUPR). The
above methods used knowledge from heterogeneous information from different
data sources to predict lncRNA-disease association and not consider network
structure features. AUC and AUPR values of all LDA prediction models were
given in Table 3. The AUC and AUPR values of all methods except DBNLDA
were taken from [12] and [22]. It was evident from the table that DBNLDA
reported second best AUC (0.96) which is closer (1.6% less) to the highest AUC
value reported by RFLDA. Moreover, DBNLDA outperforms all other methods
in terms of AUPR values, where DBNLDA have 0.968 which is 18.9% better
than the second highest value (RFLDA). These results show that DBNLDA
predicts lncRNA-disease associations effectively.
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Table 2: Accuracy of the model based on feature combinations
Experiment Feature Accuracy
Exp 1 only Node2vec featues 0.817
Exp 2 Node2vec, DBN subnetwork-1 and 0.896
DBN subnetwork-2
Exp 3 Node2vec, DBN subnetwork-1, 0.956
DBN subnetwork-2 and DBN-combined
Table 3: Comparison of performance with state-of-the-art methods
Method AUC AUPR
MFLDA [14] 0.626 0.066
SIMCLDA [13] 0.746 0.095
LDAP [17] 0.863 0.166
Ping’s Method [34] 0.871 0.219
GAMCLDA [22] 0.907 0.037
CNNLDA [19] 0.952 0.251
GCNLDA [20] 0.959 0.223
RFLDA [12] 0.976 0.779
DBNLDA 0.960 0.968
3.4. Case studies
To further investigate the ability of DBNLDA in predicting significant lncRNA-
disease associations, case studies on breast cancer, lung cancer and stomach
cancer were conducted. For this study, first trained the DBNLDA model on
a dataset containing all lncRNA-disease associations except the validated as-
sociation between lncRNAs and the disease of interest (breast/lung/stomach
cancer). Then the association score for all lncRNAs to the particular disease
was calculated using the trained model and analysed the top 15 candidate lncR-
NAs for each disease. Tables 4,5, and 6 show the top 15 candidate lncRNAs
in breast/lung/stomach cancer, predicted by DBNLDA. The evidence column
shows the reference to the associations either from reference databases or liter-
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Table 4: Top 15 DBNLDA predicted lncRNAs associated with breast cancer
lncRNA Rank Evidence
GAS5 1 Lnc2Cancer
DLEU2 2 LncRNADisease
HCP5 3 Literature (PMID: 31864836) [35]
HOTAIR 4 LncRNADisease, Lnc2Cancer
MEG3 5 LncRNADisease, Lnc2Cancer
HULC 6 Lnc2Cancer
BCYRN1 7 LncRNADisease
HOTTIP 8 Lnc2Cancer
UCA1 9 LncRNADisease, Lnc2Cancer
CDKN2B-AS1 10 LncRNADisease
NEAT1 11 LncRNADisease, Lnc2Cancer
TUG1 12 LncRNADisease, Lnc2Cancer
AFAP1-AS1 13 Lnc2Cancer
MIR100HG 14 Literature (PMID:30042378) [36]
TINCR 15 Lnc2Cancer
ature.
It was found that 13 (86.67%) lncRNAs associated with breast cancer pre-
dicted by DBNLDA were also confirmed by lnc2cancer or LncRNADisease database.
For the two unconfirmed predictions, we could find the evidence from recent
publications. In the case of lung cancer, among the top 15 predicted lncRNAs,
10 were confirmed by reference databases and remaining were reported in recent
literature. In case of stomach cancer, DBNLDA could predict 12 associations
reported either by reference databases or literature. The three new associations
(HCP5, HCG4 and MIR99AHG, indicated by ’*’ in Table 6) which could be
considered as new suggestions for further laboratory validations. The detailed
comparison of LDA prediction by DBNLDA is available in SupplementaryTable-
S2.xls.
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Table 5: Top 15 DBNLDA predicted lncRNAs associated with lung cancer
lncRNA Rank Evidence
TUG1 1 Literature (PMID:31532756) [37]
PVT1 2 Lnc2Cancer
AFAP1-AS1 3 LncRNADiease, Lnc2Cancer
XIST 4 Literature (PMID: 28448993) [38]
CCAT2 5 LncRNADisease
MALAT1 6 LncRNADiease, Lnc2Cancer
HOTTIP 7 LncRNADiease, Lnc2Cancer
SOX2-OT 8 LncRNADiease
HULC 9 Literature (PMID:30575912) [39]
MIR155HG 10 Literature (PMID:32129458) [40]
CDKN2B-AS1 11 Literature (PMID:29541247) [41]
BANCR 12 LncRNADiease, Lnc2Cancer
BCYRN1 13 LncRNADiease
UCA1 14 LncRNADiease, Lnc2Cancer
H19 15 LncRNADiease, Lnc2Cancer
4. Conclusion
Identifying disease-associated lncRNA is a necessary step in discerning the
functional roles of lncRNAs in the disease mechanism. In this work, we devel-
oped DBNLDA, a deep belief network-based model for lncRNA-disease associ-
ation prediction. This work integrates information of lncRNA, miRNA, disease
interactions, and functional similarities to construct heterogeneous networks.
Then DBN based latent representations of lncRNAs and diseases are used to
predict the lncRNA-disease association accurately. The cross-validation con-
firmed that DBNLDA has comparable performance in terms of AUC and signif-
icant improvement in terms of AUPR. Case studies on breast cancer, lung cancer
and stomach cancer show the ability of DBNLDA to predict potential disease-
associated lncRNAs. The model could be extended further with multi-modal
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Table 6: Top 15 DBNLDA predicted lncRNAs associated with stomach cancer.
lncRNA Rank Evidence
MIR17HG 1 Literature (PMID:26837962) [42]
BCYRN1 2 Literature (PMID:29435146) [43]
BANCR 3 LncRNADisease
HCP5 4 *
AFAP1-AS1 5 LncRNADisease
HNF1A-AS1 6 LncRNADisease, Lnc2Cancer
NALT1 7 Literature (PMID:31802831) [44]
DANCR 8 Lnc2Cancer
MIR99AHG 9 *
GAS5 10 LncRNADisease, Lnc2Cancer
HULC 11 LncRNADisease, Lnc2Cancer
HCG4 12 *
XIST 13 LncRNADisease, Lnc2Cancer
HOTTIP 14 LncRNADisease, Lnc2Cancer
UCA1 15 LncRNADisease, Lnc2Cancer
data such as lncRNA drug-target interactions and lncRNA-epigenetic-disease
interactions.
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